Alzheimer's disease (AD), a neurodegenerative disease involving loss of cognitive function and memory, affects more than 35 million people worldwide (Querfurth & LaFerla, 2010). However, despite the remarkable progress achieved in AD research (Sanabria-Castro, Alvarado-Echeverria, & Monge-Bonilla, 2017), its exact pathogenesis is not fully understood and effective therapies for AD do not currently exist. During my research on the pathogenesis of psoriasis and the therapeutic mechanisms of anti-interleukin-17A (anti-IL-17A) (Appendix) and anti-interleukin-23 (anti-IL-23) antibodies on psoriasis (Katayama, 2018), I considered whether these antibodies would also be effective against AD.